SMITH & NEPHEW PLC SNN

Healthcare SIC 3842 - Orthopedic, Prosthetic & Surgical Appliances & Supplies NYSE

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue ————————$4.76B$4.67B
Operating income $794.0M$657.0M$425.0M$450.0M$593.0M$295.0M$815.0M$863.0M$934.0M$801.0M
Net income $625.0M$412.0M$263.0M$223.0M$524.0M$448.0M$600.0M$663.0M$767.0M$784.0M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets $10.46B$10.35B$9.99B$9.97B$10.92B$11.01B$9.30B$8.06B$7.87B$7.34B
Total equity $5.29B$5.26B$5.22B$5.26B$5.57B$5.28B$5.14B$4.87B$4.64B$3.96B

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-028258.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
  • Cost of revenue
Revenue, Gross profit, Net income, Cost of revenue by fiscal year, in US dollars The same figures are in the table below this chart. 0 2B 4B 6B Revenue, FY2016: 4.7B Net income, FY2016: 784M Revenue, FY2017: 4.8B Net income, FY2017: 767M Net income, FY2018: 663M Net income, FY2019: 600M Net income, FY2020: 448M Net income, FY2021: 524M Net income, FY2022: 223M Net income, FY2023: 263M Net income, FY2024: 412M Net income, FY2025: 625M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $4.67B $4.76B — — — — — — — —
Gross profit — — — — — — — — — —
Net income $784.0M $767.0M $663.0M $600.0M $448.0M $524.0M $223.0M $263.0M $412.0M $625.0M
Cost of revenue — — — — — — — — — —

Others in SIC 3842

TickerCompanyMarket capP/ERevenue growth
ISRG INTUITIVE SURGICAL INC $129.55B 46.6x 20.5%
EW Edwards Lifesciences Corp $51.82B 49.1x 11.5%
STE STERIS plc $21.90B 28.3x 8.7%
ZBH ZIMMER BIOMET HOLDINGS, INC. $18.71B 27.6x 7.2%
ALGN ALIGN TECHNOLOGY INC $11.27B 28.1x 0.9%
MSA MSA Safety Inc $7.28B 26.6x 3.7%
ESTA ESTABLISHMENT LABS HOLDINGS INC. $2.21B — 27.1%
CDRE Cadre Holdings, Inc. $1.27B 29.2x 7.5%